Podcasts about Opioid use disorder

Listen in as our expert panel discusses medications for management of opioid use disorder. They'll review strategies to optimize buprenorphine use and clarify the role of methadone and naltrexone.Special guest:Tyler J. Varisco, PharmD, PhDUniversity of Houston College of Pharmacy Assistant Professor, Department of Pharmaceutical Health Outcomes and PolicyAssistant Director, The PREMIER CenterYou'll also hear practical advice from panelists on TRC's Editorial Advisory Board:Stephen Carek, MD, CAQSM, DipABLM, Clinical Associate Professor of Family Medicine for the Prisma Health/USC School of Medicine Greenville Family Medicine Residency Program at the University of South Carolina School of Medicine, GreenvilleCraig D. Williams, PharmD, FNLA, BCPS, Clinical Professor of Pharmacy Practice at the Oregon Health and Science UniversityFor the purposes of disclosure, Dr. Varisco reports a financial relationship [cardiology, inflammatory bowel disease] with HEALIX Infusion Therapy (research consultant).The other speakers have nothing to disclose.  All relevant financial relationships have been mitigated.This podcast is an excerpt from one of TRC's monthly live CE webinars, the full webinar originally aired in March 2025.TRC Healthcare offers CE credit for this podcast. Log in to your Pharmacist's Letter, Pharmacy Technician's Letter,or Prescriber Insights account and look for the title of this podcast in the list of available CE courses.Claim CreditThe clinical resources mentioned during the podcast are part of a subscription to Pharmacist's Letter, Pharmacy Technician's Letter, and Prescriber Insights: FAQ: Management of Opioid Use DisorderChart: Treatment of Opioid WithdrawalFAQ: Treatment of Acute Pain in Opioid Use DisorderFAQ: Meds for Opioid OverdoseSend us a textIf you're not yet a subscriber, find out more about our product offerings at trchealthcare.com. Follow, rate, and review this show in your favorite podcast app. Find the show on YouTube by searching for ‘TRC Healthcare' or clicking here. You can also reach out to provide feedback or make suggestions by emailing us at ContactUs@trchealthcare.com.

INterview with nurse practitioner Theresa Baxter

Hospital Addiction Consultation Service and Opioid Use Disorder Treatment JAMA Internal Medicine While medication for opioid use disorder (MOUD) is effective, many patients with OUD do not receive it, particularly in hospitalized settings. In this randomized trial they evaluated the Substance Use Treatment and Recovery Team (START) model, a team of an addiction medicine provider and a care manager, and provided motivational interviewing, discharge planning and telephone follow-up for one month. Patients who received the START intervention were more likely to receive MOUD (aRR=2.10) and connect to OUD care after discharge (aRR=1.49). In addition, these patients were more likely to have an OUD-focused discharge plan (aRR=1.8), initiate or continue MOUD post discharge (aRR=1.71), and see a clinician for OUD post discharge (aRR=1.89). These findings support use of hospital-based addiction consult services to address this healthcare gap.   Read this issue of the ASAM Weekly Subscribe to the ASAM Weekly Visit ASAM

Interview with Itai Danovitch, MD, author of Hospital Addiction Consultation Service and Opioid Use Disorder Treatment: The START Randomized Clinical Trial, and Michael A. Incze, MD, MSEd, author of Mortality Among Veterans With Opioid Use Disorder After Medical Hospitalization. Hosted by Eve Rittenberg, MD. Related Content: Hospital Addiction Consultation Service and Opioid Use Disorder Treatment Mortality Among Veterans With Opioid Use Disorder After Medical Hospitalization When Usual Care Is Subpar Care for Hospitalized Patients With Opioid Use Disorder

Interview with Itai Danovitch, MD, author of Hospital Addiction Consultation Service and Opioid Use Disorder Treatment: The START Randomized Clinical Trial, and Michael A. Incze, MD, MSEd, author of Mortality Among Veterans With Opioid Use Disorder After Medical Hospitalization. Hosted by Eve Rittenberg, MD. Related Content: Hospital Addiction Consultation Service and Opioid Use Disorder Treatment Mortality Among Veterans With Opioid Use Disorder After Medical Hospitalization When Usual Care Is Subpar Care for Hospitalized Patients With Opioid Use Disorder

Tips to optimize your health

Tips to optimize your health Listen to the latest episode of Live Foreverish as Drs. Mike and Crystal discuss the range of fiber intake found to decrease risk of arthritis; how to manage lipids with lutein; benefits of adding one cup of pomegranate juice to meds for opioid cravings; and best dose of CoQ10 for migraine. #LELearn

About this episode: People come to the emergency department seeking all kinds of urgent care. What if they could also get treatment for opioid addiction? In this episode: a look at how one rural hospital started prescribing buprenorphine to ER patients, and how scaling up treatment while reducing stigma at hospitals across the US is now helping thousands of patients every year. Guest: Arianna Campbell is an emergency department and addiction medicine PA at Marshall Medical Center in Placerville, California. Host: Dr. Josh Sharfstein is vice dean for public health practice and community engagement at the Johns Hopkins Bloomberg School of Public Health, a faculty member in health policy, a pediatrician, and former secretary of Maryland's Health Department. Show links and related content: USACS Physician Assistant, Ariana Campbell, PA-C, Aims to Eliminate the Stigma of Substance Use Through Education and Intervention—The Shift Blog The New Federal Regulations Aimed At Making Methadone More Accessible—And Less Stigmatizingcvb x—Public Health On Call (April 2024) A New Type of Overdose Response—Public Health On Call (March 2023) Transcript information: Looking for episode transcripts? Open our podcast on the Apple Podcasts app (desktop or mobile) or the Spotify mobile app to access an auto-generated transcript of any episode. Closed captioning is also available for every episode on our YouTube channel. Contact us: Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website. Follow us: @‌PublicHealthPod on Bluesky @‌JohnsHopkinsSPH on Instagram @‌JohnsHopkinsSPH on Facebook @‌PublicHealthOnCall on YouTube Here's our RSS feed Note: These podcasts are a conversation between the participants, and do not represent the position of Johns Hopkins University.

In this episode, Dr. Ekaterina Pivovarova joins host Shawn McNeil to discuss the findings from her new article Collaborating With Jails to Provide Community-based Medication for Opioid Use Disorder: Qualitative Perspectives From MOUD Treatment Providers. Dr. Pivovarova is a licensed clinical psychologist and an associate professor in the Department of Family Medicine and Community Health at the University of Massachusetts Chan Medical School. - Article link: Collaborating With Jails to Provide Community-based Medication for Opioid Use Disorder: Qualitative Perspectives From MOUD Treatment Providers

Dr. David Krag and his team are sifting through around 43,000 studies about opioids and addiction to create an easy-to-access research database.

In today's episode, we explore the evolving landscape of buprenorphine prescribing through telemedicine with Dr. Stuart Gitlow, a distinguished expert in addiction medicine. Dr. Gitlow returns to discuss the Biden administration's new ruling that enables providers to prescribe buprenorphine via telehealth, including audio-only visits, without requiring initial in-person evaluation.Building on our previous conversation about the elimination of the DATA waiver, we examine how physicians have responded to these expanded prescribing capabilities. Dr. Gitlow shares insights from his extensive experience with telemedicine during COVID-19 and addresses the implications of allowing 6-month prescriptions through virtual visits.We also discuss critical aspects of this new framework, including pharmacy verification requirements and the role of emergency departments in initiating buprenorphine treatment. Join us for this timely conversation about expanding access to addiction treatment while maintaining appropriate safeguards and quality of care.For listeners new to our series, we recommend listening to our earlier episode "History and the Elimination of the DATA Waiver" featuring Dr. Gitlow, where we explored the historical context of addiction treatment regulations.

About this episode: A new report from the Bloomberg American Health Initiative finds that the U.S. lags behind many other high-income countries in life expectancy. In this report, researchers found that babies born 40 years ago in the U.S. and U.K could expect to live to the same age. Today, however, life expectancy is nearly three years shorter for those on our side of the Atlantic Ocean. In this episode: a look at the four main causes of death driving this gap—all of which are preventable—and how one of the world's richest countries that spends the most on healthcare is continually failing to improve the health of its people. Guest: Dr. Josh Sharfstein is vice dean for public health practice and community engagement at the Johns Hopkins Bloomberg School of Public Health, a faculty member in health policy, a pediatrician, and former secretary of Maryland's Health Department. Host: Stephanie Desmon, MA, is a former journalist, author, and the director of public relations and communications for the Johns Hopkins Center for Communication Programs, the largest center at the Johns Hopkins Bloomberg School of Public Health. Show links and related content: A Tale of Two Countries: The Life Expectancy Gap Between the United States and the United Kingdom—The Bloomberg American Health Initiative Americans Die Younger Than U.K. Counterparts Due to Four Preventable Causes—Johns Hopkins Bloomberg School of Public Health Expanding Access to Methadone Treatment for Opioid Use Disorder in Carceral Settings—Johns Hopkins Bloomberg School of Public Health Contact us: Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website. Follow us: @‌PublicHealthPod on X @‌JohnsHopkinsSPH on Instagram @‌JohnsHopkinsSPH on Facebook @‌PublicHealthOnCall on YouTube Here's our RSS feed

  Evaluation and Credit:  https://www.surveymonkey.com/r/medchat74 Target Audience This activity is targeted toward primary care physicians and advanced providers. Statement of Need With the 2023 DEA regulation changes, physicians can now treat patients with Opioid Use Disorder (OUD) without requiring an X waiver. As the demand for treatment providers rises, primary care providers are pivotal in addressing this gap by initiating OUD treatments. Given that primary care often serves as the first point of contact within the healthcare system, it's crucial for providers to identify patients who could benefit from OUD treatment. However, many providers fail to recognize these patients and may refer them elsewhere, missing opportunities for immediate care. Objectives Describe screening guidelines and key diagnostic criteria for Opioid Use Disorder (OUD) Discuss effective medications for the treatment of opioid use disorder (MOUD). Review treatment strategies for MOUD treatment including guidelines for detox in the primary care setting. ModeratorJames T. Jennings, M.D., MBA Executive Medical Director Norton Medical Group Norton Healthcare Louisville, Kentucky SpeakerKelly Cooper, M.D., MPH, FASAM Medical Director Addiction Services Norton Behavioral Medicine Norton Healthcare Louisville, Kentucky  Moderator, Speaker and Planner Disclosures  The planners, moderator and speaker of this activity do not have any relevant financial relationships with ineligible companies to disclose.   Commercial Support  There was no commercial support for this activity.  Physician Credits Accreditation Norton Healthcare is accredited by the Kentucky Medical Association to provide continuing medical education for physicians. Designation Norton Healthcare designates this enduring material for a maximum of .75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. HB1This program has been approved for .75 HB1 credit hours by the Kentucky Board of Medical Licensure, ID# 1124-H.75-NHC11a.  For more information about continuing medical education, please send an email to cme@nortonhealthcare.org.  Nursing CreditsNorton Healthcare Institute for Education and Development is approved with distinction as a provider of nursing continuing professional development by the South Carolina Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation. This continuing professional development activity has been approved for 0.75 ANCC CE contact hours. Norton Healthcare is also a Kentucky Board of Nursing (KBN) approved provider. This activity has also been approved by Norton Healthcare for 0.75 KBN Pharmacology contact hour, which expires 12/31/2026. KBN approval of a continuing education provider does not constitute endorsement of program content.  This activity/session meets 0.75 CE contact hour (of the 3.0 contact hour annual requirement) of approved pain management and addiction disorder CE required by the Kentucky Board of Nursing (KBN) for annual license renewal for APRNs that are registered with the DEA and have a Prescription Drug Monitoring Program (PDMP) account– 201 KAR 20:215.” – 4-0002-12-26-004. In order for nursing participants to obtain credits, they must claim attendance by attesting to the number of hours in attendance.  For more information related to nursing credits, contact Sally Sturgeon, DNP, RN, SANE-A, AFN-BC at (502) 446-5889 or sally.sturgeon@nortonhealthcare.org. Resources for Additional Study/References Reframing conceptualizations of primary care involvement in opioid use disorder treatment; Chiu and Sud BMC Primary Care (2024) 25:356. Integrating Routine Screening for Opioid Use Disorder into Primary Care Settings: Experiences from a National Cohort of Clinics; J Gen Intern Med 38(2):332–40; DOI: 10.1007/s11606-022-07675-2.   Resources American Society of Addiction Medicine Provider Clinical Support System U.S. Centers for Disease Control and Prevention    Date of Original Release | Jan. 2025; Information is current as of the time of recording. Course Termination Date | Jan. 2028 Contact Information | Center for Continuing Medical Education; (502) 446-5955 or cme@nortonhealthcare.org Norton Healthcare, a not for profit health care system, is a leader in serving adult and pediatric patients throughout Greater Louisville, Southern Indiana, the commonwealth of Kentucky and beyond. More information about Norton Healthcare is available at NortonHealthcare.com.

In episode 53 we discuss an article comparing treatment retention and mortality in patients who are prescribed methadone vs. buprenorphine/naloxone for treatment of opioid use disorder.    Nosyk B, Et al. Buprenorphine/Naloxone vs Methadone for the Treatment of Opioid Use Disorder. JAMA. 2024 Oct 17.     We also discuss the Modernizing Opioid Treatment Access Act, engaging non-abstinent patients in treatment, and hostility to medications with the recovery community.    Modernizing Opioid Treatment Access Act (MOTAA) (H.R.1359 / S. 644)  ASAM: Engagement and Retention of Nonabstinent Patients in Substance Use Treatment  STAT News: The recovery community says it offers refuge from opioid addiction. But it's still hostile to lifesaving addiction medications  ---  This podcast offers category 1 and MATE-ACT CME credits through MI CARES and Michigan State University. To get credit for this episode and others, go to this link to make your account, take a brief quiz, and claim your credit. To learn more about opportunities in addiction medicine, visit MI CARES.  CME: https://micaresed.org/courses/podcast-addiction-medicine-journal-club/   ---  Original theme music: composed and performed by Benjamin Kennedy  Audio editing: Michael Bonanno  Executive producer: Dr. Patrick Beeman  A podcast from Ars Longa Media  ---  This is Addiction Medicine Journal Club with Dr. Sonya Del Tredici and Dr. John Keenan. We practice addiction medicine and primary care, and we believe that addiction is a disease that can be treated. This podcast reviews current articles to help you stay up to date with research that you can use in your addiction medicine practice.     The best part of any journal club is the conversation. Send us your comments on social media or join our Facebook group.  Email: addictionmedicinejournalclub@gmail.com   Facebook: @AddictionMedJC  Facebook Group: Addiction Medicine Journal Club  Instagram: @AddictionMedJC   Threads: @AddictionMedJC  YouTube: addictionmedicinejournalclub   Twitter/X: @AddictionMedJC   Addiction Medicine Journal Club is intended for educational purposes only and should not be considered medical advice. The views expressed here are our own and do not necessarily reflect those of our employers or the authors of the articles we review. All patient information has been modified to protect their identities. 

Every week, the equivalent of a high-school classroom's worth of students (an average of 22 adolescents) dies of drug overdoses in the United States. Join us and expert guest Dr. Scott Hadland (Mass General for Children, Harvard Medical School) as we explore Opioid Use Disorder, a rapidly evolving disease affecting our youth. Dr. Hadland provides a big picture understanding of this complex problem but also gives practical day to day tools for tackling OUD in teens. Come and be surprised by how much better you can navigate opioid use among teens. 

The Morning Agenda is supported by the City of Lancaster helping create a magical holiday season in the city by offering shopping from nearly 150 small businesses to find gifts for friends and family. More details at VisitLancasterCity.com. Pennsylvania drivers can expect to spend less at the gas pump over this Thanksgiving holiday than they spent last year.  Rachel McDevitt has more on recent trends in gas prices. Treatment options for opioid use disorder in Pennsylvania jails and prisons are improving. That's according to the Pennsylvania Institutional Law Project. But people who are incarcerated still face challenges in getting addiction treatment.  Nicole Leonard reports the nonprofit, legal aid organization has launched a new storytelling series to focus on gaps in care. A commission responsible for overseeing the state's opioid settlement money says several Philadelphia projects and proposals do not fall under acceptable uses under lawsuit settlement terms. Nicole Leonard has the details. Pennsylvania's Department of Education will have a new Secretary starting early December. Tom Riese reports that Dr. Khalid Mumin gave his two weeks' notice Friday.  Support WITF: https://www.witf.org/support/give-now/See omnystudio.com/listener for privacy information.

ABOUT THE EPISODE:In 2020, a documentary film titled "The Final Fix" introduced the public to a new treatment for opioid use disorder.  The claims of the neuroelectric therapy (NET) device are bold: opiate detox in 3-5 days with little or no withdrawal symptoms, discomfort, or cravings. Since the film's release, I have personally known three people who acquired NET treatment for their kids, including two from the Hopestream community. All have had great experiences.In 2021, double-blind trials of more than 100 people experiencing opioid use disorder began and the NET Device for OUD treatment was approved by the FDA in May of this year.In this episode, I spoke with Jeff Lott, director of communications at NET Recovery. We discussed the surprising origins of this medical technology, how NET was accidentally discovered by a Scottish surgeon working in Hong Kong, the fact that its groundbreaking results are not a panacea for recovery, and plans for the future of the NET Device for widespread adoption and use in the treatment industry.EPISODE RESOURCES:A randomized, sham-controlled, quintuple-blinded trial to evaluate the NET device as an alternative to medication for promoting opioid abstinenceRevolutionary Kentucky-based opioid use disorder treatment device receives FDA approvalNET Recovery websiteIsiah House NET Recovery InformationThis podcast is part of a nonprofit called Hopestream CommunityLearn about The Stream, our private online community for momsLearn about The Woods, our private online community for dadsFind us on Instagram: @hopestreamcommunityDownload a free e-book, Worried Sick: A Compassionate Guide For Parents When Your Teen or Young Adult Child Misuses Drugs and AlcoholHopestream Community is a registered 501(c)3 nonprofit organization and an Amazon Associate. We may make a small commission if you purchase from our links.

How does access to pain medicine differ between nations and how does this impact public health? For more information checkout: Pain management in low- and middle-income countries (PMID: 33456843), Guide to Pain Management in Low-Resource Settings (Author: International Association for the Study of Pain), Chronic pain: a review of its epidemiology and associated factors in population-based studies (PMID: 31079836), Vital Signs: Prescription Opioid Pain Reliever Use During Pregnancy — 34 U.S. Jurisdictions, 2019 (PMID: 33180599), Maternal and Infant Characteristics Associated with Opioid Use During Pregnancy: A Population-Based Study Using Birth Certificate Data (PMID: 30550261), Trends, Patterns, and Maternal Characteristics of Opioid Prescribing During Pregnancy in a Large Population-based Cohort Study (PMID: 32054599), Neonatal Outcomes Associated with Maternal Use of Opioids During Pregnancy (PMID: 31013277), Addressing the Opioid Epidemic in Low-Income and High-Minority Communities (PMID: 31546158), Disparities in Access to Non-Opioid Pain Management Options in Medicaid Populations (PMID: 31167534), Socioeconomic Disparities and Neonatal Abstinence Syndrome: Implications for Maternal and Child Health (PMID: 30117882), The Impact of Socioeconomic and Racial Disparities on Opioid Use Disorder in Pregnancy (PMID: 32746981), Barriers to Accessing Addiction Treatment and Maternal Health Services Among Medicaid Populations (PMID: 30392954), Maternal Use of Opioids During Pregnancy and Congenital Malformations: A Systematic Review (PMID: 29376100), CDC: Centers for Disease Control and Prevention, PRAMS | CDC: Pregnancy Risk Assessment Monitoring System | Centers for Disease Control and Prevention, NVSS | CDC: National Vital Statistics Sytem | Centers for Disease Control and Prevention, NIDA | NIH: National Institute on Drug Abuse | National Institutes of Health, ChatGPT - Open AI, CANVA: Visual Suite for Everyone.  

In this episode, we explore the critical risks of opioid use among seniors, including addiction, overdose, and the dangerous side effects that can worsen existing health conditions. We speak with David Reeser, CEO of OpiAID, to understand the impact of Opioid Use Disorder (OUD) on aging parents and their families, highlighting why awareness is essential for everyone. OpiAID is revolutionizing OUD treatment with remote patient monitoring, biometric insights, and personalized care plans that go beyond the clinical setting. As the opioid crisis impacts families nationwide, this episode provides crucial insights for seniors and their loved ones to safely navigate opioid-related challenges.

Diabetes Core Update is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association's four science and medical journals – Diabetes, Diabetes Care, Clinical Diabetes, and Diabetes Spectrum. Each episode is approximately 25 minutes long and presents 5-6 recently published articles from ADA journals. Intended for practicing physicians and health care professionals, Diabetes Core Update   discusses how the latest research and information published in journals of the American Diabetes Association are relevant to clinical practice and can be applied in a treatment setting. Welcome to diabetes core update where every month we go over the most important articles to come out in the field of diabetes. Articles that are important for practicing clinicians to understand to stay up with the rapid changes in the field.  This issue will review: 1.     Insulin Efsitora versus Degludec in Type 2 Diabetes without Previous Insulin Treatment   2.     Semaglutide and Opioid Overdose Risk in Patients With Type 2 Diabetes and Opioid Use Disorder 3.     Associations of Diabetes and Prediabetes with Mortality and Life Expectancy in China: A National Study 4.     GLP-1 Medication Use for Type 2 Diabetes in the US 5.     Healthcare Utilization and Cost Associated with Empagliflozin in Older Adults with Type 2 Diabetes   For more information about each of ADA's science and medical journals, please visitwww.diabetesjournals.org. Hosts: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Director, Family Medicine Residency Program, Chair-Department of Family Medicine, Abington Jefferson Health

Buprenorphine/Naloxone vs Methadone for the Treatment of Opioid Use Disorder JAMA Network This population-based retrospective cohort study assessed whether the use of buprenorphine/naloxone is associated with lower risk of treatment discontinuation and mortality compared with methadone. It included 30,891 individuals initiating treatment for the first time during the study period and found that  the risk of treatment discontinuation was higher among recipients of buprenorphine/naloxone compared with methadone (88.8% vs 81.5% within 24 months). The risk of mortality was low while in either form of treatment (0.08% vs 0.13%).  Individuals receiving methadone had a lower risk of treatment discontinuation compared with those who received buprenorphine/naloxone. The risk of mortality while receiving treatment was similar between medications.   Read this issue of the ASAM Weekly Subscribe to the ASAM Weekly Visit ASAM

Dr. Kelly S. Ramsey, an Addiction Medicine and Harm Reduction Consultant, discusses a Q&A she wrote for Johns Hopkins about the expansion of methadone treatment access; Matta Sannoh, ASTHO Chronic Disease Risk Factors Senior Analyst, tells us about ASTHO's Menthol Capacity Building web page; and an ASTHO blog article details how Washington State continues to improve emergency preparedness. Johns Hopkins Bloomberg School of Public Health Web Page: Expanding Access to Methadone Treatment for Opioid Use Disorder in Carceral Settings LinkedIn Web Page: Kelly S. Ramsey ASTHO Blog Article: Menthol Capacity Building ASTHO Blog Article: How Washington State Leverages Data to Improve Emergency Preparedness  

Host Shawn McNeil, MD, is joined by Michelle Lofwall, MD, DFAPA, DFASAM,  a professor in the Department of Behavioral Science and Psychiatry at the University of Kentucky and Medical Director of UK's Robert Straus and First Bridge Clinics, which provide comprehensive OUD treatment within the UK Center on Drug and Alcohol Research. Dr. Lofwall and  her co-authors examined the relationship between the dose in the early stages of treatment and the subsequent risk of death and found some surprising results.   Higher First 30-Day Dose of Buprenorphine for Opioid Use Disorder Treatment Is Associated With Decreased Mortality   Journal of Addiction Medicine 18(3):p 319-326, 5/6 2024 May-June 2024

In this episode of Inspired Nonprofit Leadership, host Sarah Olivieri speaks with Gary Mandel, founder and CEO of Shatterproof, a national nonprofit working to reverse the addiction crisis in America. Gary shares his personal journey of founding Shatterproof after losing his son to addiction, the organization's approach to implementing science-based addiction treatment, combating stigma, and creating systemic change. The conversation covers Shatterproof's strategic growth, critical partnerships, public policy efforts, and lessons learned from Gary's extensive business background.   Gary Mendell is the founder and CEO of Shatterproof, a national nonprofit focused on reversing the course of the addiction crisis in America. After losing his son Brian to addiction in 2011, Gary founded Shatterproof to spare other families the tragedy that his suffered. Gary has grown Shatterproof to over $20M since founding it in 2012 and has become a national leader in the addiction field creating solutions that will ensure that substance use disorder will be prevented and treated for generations to come. He is a frequent speaker on how our society can end the stigma unjustly associated with addiction, has been honored numerous times for his leadership related to reversing the course of the opioid epidemic, testified in front of the President's Commission on Combating Drug Addiction and the Opioid Crisis, testified before the U.S. Senate Committee on Finance on Treating Substance Misuse in America, and has been a guest several times on CNBC and MSNBC to provide his perspective on common sense solutions to the opioid epidemic, and his opinions are frequently reflected in The Wall Street Journal, Forbes, and The Washington Post. Mr. Mendell is a member of the National Leadership Steering Team for the Grand Challenge to Eliminate Stigma around Mental Health and Substance Use Disorder with the Huntsman Mental Health Institute, a member of the National Quality Forum's Technical Expert Panel for Opioid and Opioid Use Disorder and is an advisory member of The Opioid Policy Research Collaborative at the Heller School for Social Policy and Management at Brandeis University. Gary has spent decades as an entrepreneur. He founded HEI Hotels & Resorts, a multi-billion-dollar company that oversees a portfolio of approximately 85 first class hotels. He raised and managed $1.2 billion in discretionary capital from some of the most prestigious universities in the United States and managed more than $2 billion in assets. He is also a former trustee and president of Starwood Lodging Trust. That business-world experience gives him a unique perspective in running a nonprofit organization like Shatterproof. Mr. Mendell received his B.S. from Cornell University's School of Hotel Administration and his MBA with distinction from the Wharton School at the University of Pennsylvania. Here's what to expect during the episode: Challenges and Strategies in Nonprofit Leadership The Role of Media and Partnerships in Growth Addressing Stigma and Measuring Success Scaling and Infrastructure in Nonprofits Connect with Gary: Facebook:https://www.facebook.com/ShatterproofHQ X: https://x.com/ShatterproofHQ Instagram:https://www.instagram.com/weareshatterproof/ LinkedIn:https://www.linkedin.com/company/shatterproof Our website is shatterproof.org Cortny McKean: gmendell@shatterproof.org Sponsored Resource Join the Inspired Nonprofit Leadership Newsletter for weekly tips and inspiration for leading your nonprofit! Access it here >> Be sure to subscribe to Inspired Nonprofit Leadership so that you don't miss a single episode, and while you're at it, won't you take a moment to write a short review and rate our show? It would be greatly appreciated! Let us know the topics or questions you would like to hear about in a future episode. You can do that and follow us on LinkedIn. Connect with Sarah: On LinkedIn>> On Facebook>> Subscribe on YouTube>>

Virtual reality-based Mindfulness-Oriented Recovery Enhancement (MORE-VR) as an adjunct to medications for opioid use disorder: a Phase 1 trial 

Two-time Emmy and three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald, interviewed Dr. Michael Giles. Our Virtual Dosing Window™ allows patients to record their take-homes by using a phone or computer to scan the QR code on their methadone bottles and then recording a video of themselves dosing for their care team to review. This patented solution helps build trust between OTP patients and their care teams, empowering clinics with real-time insights to make informed treatment decisions. Sonara also increases patients' likelihood of earning more take homes, which in turn improves program retention rates. Since starting Sonara in 2020, Dr. Giles has expanded the solution to a network of modernized, tech-enabled clinics in 11 states that provide accessible, patient-centered care for individuals struggling with OUD. Sonara® is on a mission to support OTP patients, with a remote dosing solution that makes it easier for people with opioid use disorder to commit to their methadone treatment programs, so they can get their lives back. Sonara provides OTPs with the confidence they need to approve more take-home doses responsibly, to improve the quality of life for patients and expand treatment accessibility for those who live farther away from clinics. Notable investors in Sonara include Mark Cuban and First Trust Capital. With Sonara, OTP patients can achieve their treatment goals without putting their lives on hold. To learn more about partnering with Sonara or bringing the Virtual Dosing Window to your OTP, visit sonarahealth.com/contact-us to get in touch. #STRAW #SHMS  Support the show: https://www.steveharveyfm.com/See omnystudio.com/listener for privacy information.

Two-time Emmy and three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald, interviewed Dr. Michael Giles. Our Virtual Dosing Window™ allows patients to record their take-homes by using a phone or computer to scan the QR code on their methadone bottles and then recording a video of themselves dosing for their care team to review. This patented solution helps build trust between OTP patients and their care teams, empowering clinics with real-time insights to make informed treatment decisions. Sonara also increases patients' likelihood of earning more take homes, which in turn improves program retention rates. Since starting Sonara in 2020, Dr. Giles has expanded the solution to a network of modernized, tech-enabled clinics in 11 states that provide accessible, patient-centered care for individuals struggling with OUD. Sonara® is on a mission to support OTP patients, with a remote dosing solution that makes it easier for people with opioid use disorder to commit to their methadone treatment programs, so they can get their lives back. Sonara provides OTPs with the confidence they need to approve more take-home doses responsibly, to improve the quality of life for patients and expand treatment accessibility for those who live farther away from clinics. Notable investors in Sonara include Mark Cuban and First Trust Capital. With Sonara, OTP patients can achieve their treatment goals without putting their lives on hold. To learn more about partnering with Sonara or bringing the Virtual Dosing Window to your OTP, visit sonarahealth.com/contact-us to get in touch. #STRAW #SHMS  See omnystudio.com/listener for privacy information.

In this episode, Provident's Craig Sager and Dan O'Brien sit down with Chris Bove, CEO of Clean Slate Centers. Together they examine the world of Medication Assisted Treatment (“MAT”), exploring the challenges MAT aims to address, the related operational and payor dynamics, and key components in driving outcomes for those struggling with addiction.

On this episode we discuss the management of opioid use disorder. We begin by describing its clinical presentations, etiologies, and pathophysiology. We then compare and contrast the efficacy, safety profiles, and appropriate use of medications for opioid use disorder, behavioral therapies, and patient monitoring in treating opioid use disorder.  Cole and I are happy to share that our listeners can claim ACPE-accredited continuing education for listening to this podcast episode! We have continued to partner with freeCE.com to provide listeners with the opportunity to claim 1-hour of continuing education credit for select episodes. For existing Unlimited (Gold) freeCE members, this CE option is included in your membership benefits at no additional cost! A password, which will be given at some point during this episode, is required to access the post-activity test. To earn credit for this episode, visit the following link below to go to freeCE's website: https://www.freece.com/ If you're not currently a freeCE member, we definitely suggest you explore all the benefits of their Unlimited Membership on their website and earn CE for listening to this podcast. Thanks for listening! We want to give a big thanks to our sponsor, High-Powered Medicine. HPM is a book/website database of summaries for over 150 landmark clinical trials. You can get a copy of HPM, written by Dr. Alex Poppen, PharmD, at the links below:  Purchase a subscription or PDF copy - https://highpoweredmedicine.com/ Purchase the paperback and hardcover - Barnes and Noble website We want to give a big thanks to our main sponsor Pyrls. Try out their drug information app today. Visit the website below for a free trial: www.pyrls.com/corconsultrx If you want to support the podcast, check out our Patreon account. Subscribers will have access to all previous and new pharmacotherapy lectures as well as downloadable PowerPoint slides for each lecture. You can find our account at the website below:  www.patreon.com/corconsultrx If you have any questions for Cole or me, reach out to us on any of the following: Text - 415-943-6116 Mike - mcorvino@corconsultrx.com Cole - cswanson@corconsultrx.com

In this episode of the Recovery Matters Podcast, host Phil welcomes Ahmed Abdel Aziz from Indivior, a global pharmaceutical company focused on addiction medicine. Ahmed introduces himself and discusses his passion for public health and addiction treatment. He highlights Indivior's commitment to transforming lives affected by substance use disorders, emphasizing the need to treat addiction as a disease, not a moral failing. Ahmed shares insights into common misconceptions about medication-assisted recovery and explains the importance of patient-centric and culturally competent care. They explore the evolving landscape of addiction recovery, including the potential of psychedelics and the principles of harm reduction. Ahmed also reflects on his personal journey and motivations for working in this field, rooted in early exposure to the pharmaceutical industry and personal experiences with friends affected by addiction. The conversation delves into broader societal perspectives on healthcare and the evolving role of big pharma in addressing public health challenges. 00:00 Introduction and Guest Welcome 00:19 Ahmed Abdel Aziz's Background and Indivior's Mission 01:33 Common Medications and Misconceptions 03:51 Ahmed's Personal Journey into Addiction Medicine 06:46 Family and Future Generations 08:46 Shifts in Addiction and Recovery Perspectives 12:37 Multiple Pathways to Recovery 22:10 Hot Topics: Psychedelics and Harm Reduction 29:27 Big Pharma and Population Health 36:41 Spirituality and Recovery Coaching 43:54 Conclusion and Final Thoughts

Petros Levounis, MD, MA, DFASAM, talks with our host, Zach, about why he chose to practice addiction medicine, including an impactful experience at the Betty Ford Center (now Hazelden Betty Ford) as a medical student. He shares his thoughts regarding stigma and his extensive writing about addiction. Dr. Levounis speaks about how his fields of study and interest (including sociology, medicine, mental health, and addiction) intersect and the ways treatment can be both unique to the individual and similar. He shares what motivates him to treat addiction every day and where he sees the field moving in the future. Dr. Levounis offers advice for those who may have a loved one with addiction and to the next generation of addiction providers. Dr. Levounis serves as professor and chair of the Department of Psychiatry and associate dean at Rutgers New Jersey Medical School. He is also the chief of service at University Hospital in Newark, New Jersey, director of the Northern New Jersey Medication Assisted Treatment Center of Excellence, and immediate past president of the American Psychiatric Association (APA). Dr. Levounis came to Rutgers from Columbia University where he served as director of the Addiction Institute of New York from 2002 to 2013. Dr. Levounis is a Phi Beta Kappa graduate of Stanford University where he studied chemistry and biophysics before receiving his medical education at Stanford University School of Medicine and the Medical College of Pennsylvania. During medical school, he researched the effects of social class on patient-physician relationships in Oxford, England, and received an MA degree in sociology from Stanford. In 1994, he moved to New York City to train in psychiatry at the New York State Psychiatric Institute of Columbia University. He graduated from Columbia earning the National Institute of Mental Health Outstanding Resident Award and went on to complete his fellowship in addiction psychiatry at New York University. Dr. Levounis has written numerous articles, monographs, and book chapters; has lectured extensively on addiction topics throughout the United States and abroad; and has been interviewed by CBS, ABC, NBC, CNN, FOX, The Martha Stewart Radio Show, The New York Times, and The Washington Post, among others. Dr. Levounis has served on the boards of the American Society of Addiction Medicine (ASAM) and the American Board of Addiction Medicine, and from 2005 to 2009 chaired the national Committee on Addiction Treatment of the APA. Dr. Levounis is a Betty Ford Scholar, a recipient of the Association of Gay and Lesbian Psychiatrists' Distinguished Service Award and the ASAM Educator of the Year Award, and a distinguished fellow of the APA and ASAM. In 2017, he was elected as an honorary member of the World Psychiatric Association. He is the 2024 recipient of The John P. McGovern Award on Addiction and Society, from ASAM. Dr. Levounis has published fourteen books including the self-help paperback Sober Siblings: How to Help Your Alcoholic Brother or Sister—and Not Lose Yourself; the textbook of Substance Dependence and Co-Occurring Psychiatric Disorders; Motivational Interviewing for Clinical Practice; The Behavioral Addictions; Becoming Mindful; LGBTQ Mental Health: The Spectrum of Gender and Sexuality; Office-Based Buprenorphine Treatment of Opioid Use Disorder, now in its second edition; and Technological Addictions. Dr. Levounis is currently working on the first textbook of Nature Therapy, which is going to be available in the fall of 2024. His books have been translated into French, German, Hungarian, Japanese, Korean, Portuguese, and Spanish. Dr. Levounis is married to actor Lukas Hassel and lives in New York City.   Links: American Psychiatric Association (APA) American Society of Addiction Medicine (ASAM) If you or someone you know is struggling with addiction, you are not alone. Treatment is available and recovery is possible. Visit ASAM's Patient Resources page for more information. The information shared in this podcast episode is for educational purposes only and should not be taken as medical advice. The views expressed in this podcast may not be those of the host or ASAM management.

Summary Brandi Mac (Host) is an Acute Care Nurse Practitioner, and mother of an adult child in recovery from substance use disorder.  Dr. Taylor Nichols, a certified addiction physician and ER doctor, discusses his journey from working in the emergency department to specializing in addiction medicine. He shares his experiences of seeing the broken healthcare system and the harm it causes to people who use drugs. Dr. Nichols emphasizes the importance of harm reduction and reducing stigma in healthcare. He also addresses misconceptions about medications like Suboxone and buprenorphine and provides insights into managing pain in patients with opioid use disorder. In this part of the conversation, Dr. Taylor Nichols discusses the process of tapering off opioids, specifically focusing on the use of buprenorphine and the medications Sublicade and Brixadi.  He explains how buprenorphine works to replace opioids in the brain and reduce withdrawal symptoms. Dr. Nichols also discusses the challenges of tapering off fentanyl and the importance of finding the right dose of buprenorphine to effectively manage withdrawal. She highlights the Bernese method as an alternative approach to tapering and explains the differences between Sublicade and Brixadi. Additionally, Dr. Nichols addresses the concerns of families and loved ones of individuals with substance use disorder, emphasizing the importance of supporting the individual's goals and providing them with evidence-based treatment options. Dr. Nichols TikTok: Click Here Dr. Nichols Website: Click Here Recovery Reform Podcast by Dr. Nichols and McCauley Sexton: Click Here Recovery Reform YouTube Channel: Click Here Article: Naloxone to Buprenorphine Chapters 00:00 Introduction and Background 03:46 Harm Reduction and Stigma 10:38 Respecting Autonomy and Challenging Stigma 14:46 Debunking Misconceptions about Naloxone and Buprenorphine 18:23 Physician Fear and the Opioid Crackdown 25:16 The Functionality of Naloxone in Suboxone 32:54 The Ceiling Effect of Buprenorphine 36:26 Managing Pain in Patients with Opioid Use Disorder 38:25 Understanding the Role of Buprenorphine 41:21 Managing Withdrawal Symptoms 44:04 Long-Acting Injectable Buprenorphine 50:43 Comparing Sublicade and Brixadi 55:27 Supporting Individuals and Families 01:02:16 Empowering Individuals to Make Decisions

Welcome to part three of our limited series where we pull back the curtain on the publication process. This episode features Family Medicine editors Sarina Schrager, MD, MS, and Octavia Amaechi, MD, advising on what to do upon receiving that dreaded rejection notification. Everybody gets papers rejected, and the reviewer's comments provide an opportunity to grow, refine your paper, and make it stronger for the next journal submission. Our editors share opportunities to refine your writing skills and keep your work out of the rejection pile. Above all else, they encourage you to remember your “why” and to keep going! Hosted by Saria Saccocio, MD, MHA, FAAFPCopyright © Society of Teachers of Family Medicine, 2024Resources:Quick Consult - formerly the Virtual Coaching ProgramSTFM Leadership through Scholarship FellowshipSTFM CERA FellowshipSTFM Medical Editing Fellowship  STFM URM Mentorship ProgramPRiMER Author Mentorship ProgramAmerican Family Physician Jay Siwek Medical Editing FellowshipJournal of the American Board of Family Medicine Research and Editing FellowshipAnnals of Family Medicine Editorial FellowshipGuest Bio:Sarina Schrager, MD, MSEditor in Chief Family MedicineSarina Schrager, MD, MS, is a professor in the University of Wisconsin's Department of Family Medicine and Community Health (UW DFMCH). She also serves as UW DFMCH's director of promotions and mentoring and as Wisconsin Research and Education Network's medical director. Prior to becoming the editor in chief of Family Medicine, she served in the same capacity at Wisconsin Medical Journal, as an editor for FPM, and on the editorial board of the Journal of the American Board of Family Medicine. Her research expertise is in residency education and faculty development, and her recent work has focused on shared decision-making in cancer screening. She obtained her MD at the University of Illinois, Chicago, her residency training as well as a primary care women's health fellowship at MacNeal Hospital, and a faculty development fellowship at UW DFMCH.Octavia Amaechi, MDDEIA Editor Family MedicineOctavia Amaechi, MD, serves as the chief of staff, a hospitalist, and Health Equity Committee chair at the Spartanburg Regional Healthcare System and as a faculty physician in the Spartanburg Regional Family Medicine Residency (SRFMR) program. She holds positions as a mentor in STFM's Leadership Through Scholarship Program, a board member of the Spartanburg County Medical Society, an annual delegate and reference committee chair of the South Carolina Medical Association, and member of the South Carolina Academy of Family Physicians Committee on Diversity, Equity, and Inclusiveness. Her expertise is in diversity, equity, inclusion, antiracism, patient and community advocacy, inpatient/hospital medicine, and MAT for Opioid Use Disorder. She completed her MD at the University of Health Sciences Antigua, her residency training a

Dr Elizabeth Salisbury-Afshar joins Ethics Talk to discuss her article, coauthored with Drs Catherine J. Livingston and Ricky N. Bluthenthal: “How Should Harm Reduction Be Included in Care Continua for Patients with Opioid Use Disorder?”  Recorded March 8, 2024.  Read the full article for free at JournalOfEthics.org

Dr Kelly Gillespie joins Ethics Talk to discuss her article, coauthored with Dr Taleed El-Sabawi: “When Medication Treatment for Opioid Use Disorder Gets Disrupted by Extra-Clinical Variables, How Should Clinicians Respond?”  Recorded March 29, 2024.  Read the full article for free at JournalOfEthics.org

The opioid epidemic is a decades long public health crisis that is only continuing to grow in severity and impact. It is currently the foremost public health crisis in the United States, with its roots tracing back to mid to late 1990s when the highly concentrated prescription pain killer Oxycontin was approved by the U.S. Food and Drug Administration in conjunction with the controversial pain as the fifth vital sign campaign, among other factors. As the U.S. government, healthcare system, and general public struggle to combat this epidemic, members of the OR/MS and analytics community are leveraging data and research to help provide support and solutions. Joining me to share their unique insight into a data-driven approach to help combat the opioid epidemic are Joyce Luo with MIT and Bartolomeo Stellato with Princeton University. Their study, “Frontiers in Operations: Equitable Data-Driven Facility Location and Resource Allocation to Fight the Opioid Epidemic," was recently published in the INFORMS journal Manufacturing & Service Operations Management.

Dave Lettrich and Dr Jim Withers join Ethics talk to discuss how street outreach programs help mitigate harms of drug use among people experiencing homelessness.  Recorded February 21, 2024.  Read the full July 2024 issue on Harm Reduction and Opioid Use Disorder for free at JournalOfEthics.org

What future military cooperation between Russia and China might look like; the effects of a new abortion law in North Carolina; limited access to medication treatment for opioid use disorder; the state of the American teacher; and considering the potential for an ‘October surprise' from North Korea. For more information on this week's episode, visit rand.org/podcast.

In this episode, Sam Ashoo, MD and T.R. Eckler, MD interview Corey Hazekamp, MD, MS, one of authors of the June 2024 Emergency Medicine Practice article, Managing Emergency Department Patients With Opioid Use DisorderCurrent State of Opioid EpidemicOverview of overdose deaths and trends.Data and statistics about opioid overdose mortality rates.Three Waves of Opioid Overdose Deaths in the U.S.Opioid Classifications and Urine Drug TestingTypes of opioids: synthetic, semi-synthetic, and natural.Urine drug testing limitations and false positives/negatives.Practical use and research on co-ingestionsEmergency Medical Services (EMS) and Pre-Hospital CareImportance of ABCs in acute opioid overdose cases.Naloxone usage trends and an empirical approach.Anecdotal insights on changing naloxone administration dosages.Clinical Management in the Emergency DepartmentBuprenorphine InitiationProtocols for initiating buprenorphine in ED settings.Assessment using the Clinical Opiate Withdrawal Scale (COWS).Safe dosing procedures for buprenorphine.Withdrawal and Overdose CareLaboratory testing recommendations.Capnography and VBG in overdose management.The role of end-tidal CO2 monitoring and respirations.Methadone vs. Buprenorphine ConsiderationsMethadone to buprenorphine transition protocols.Personal testimonials and clinical experiences in managing overdoses and withdrawal symptoms.Patient Discharge and Follow-upPreparation of discharge prescriptions.Referral to addiction medicine clinics and resources.Educating patients on continued treatment and harm reduction.

An update of our 2020 series, in which we spoke with physicians, researchers, and addicts about the root causes of the crisis — and the tension between abstinence and harm reduction. SOURCES:Gail D'Onofrio, professor and chair of emergency medicine at the Yale School of Medicine and chief of emergency services at Yale-New Haven Health.Keith Humphreys, professor of psychiatry and behavioral sciences at Stanford University.Stephen Loyd, chief medical officer of Cedar Recovery and chair of the Tennessee Opioid Abatement Council.Nicole O'Donnell, certified recovery specialist at the University of Pennsylvania's Center for Addiction Medicine and Policy.Jeanmarie Perrone, professor of emergency medicine at the University of Pennsylvania.Eileen Richardson, restaurant manager. RESOURCES:“Toward Healthy Drug Policy in the United States — The Case of Safehouse,” by Evan D. Anderson, Leo Beletsky, Scott Burris, and Corey S. Davis (The New England Journal of Medicine, 2020).“Buprenorphine Deregulation and Mainstreaming Treatment for Opioid Use Disorder,” by Leo Beletsky, Kevin Fiscella, and Sarah E. Wakeman (JAMA Psychiatry, 2018).“Emergency Department–Initiated Buprenorphine/Naloxone Treatment for Opioid Dependence,” by Gail D'Onofrio, Patrick G. O'Connor, Michael V. Pantalon, Marek C. Chawarski, Susan H. Busch, Patricia H. Owens, Steven L. Bernstein, and David A. Fiellin (JAMA, 2015).“Buprenorphine-Naloxone Therapy In Pain Management,” by Lucy Chen, Kelly Yan Chen, and Jianren Mao (National Institutes of Health, 2014).“Prevalence and Correlates of Street-Obtained Buprenorphine Use Among Current and Former Injectors In Baltimore, Maryland,” by Jacquie Astemborski, Becky L. Genberg, Mirinda Gillespie, Chris-Ellyn Johanson, Gregory D. Kirk, Shruti H. Mehta, Charles R. Schuster, and David Vlahov (U.S. National Library of Medicine National Institutes of Health, 2014).“The Promotion and Marketing of OxyContin: Commercial Triumph, Public Health Tragedy,” by Art Van Zee (U.S. National Library of Medicine National Institutes of Health, 2009). EXTRAS:"Why Is the Opioid Epidemic Still Raging?" series by Freakonomics Radio (2024)."The Opioid Tragedy, Part 1: 'We've Addicted an Entire Generation,'" by Freakonomics Radio (2020).“The Truth About the Vaping Crisis,” by Freakonomics Radio (2019).

Rapid Initiation of Injection Naltrexone for Opioid Use Disorder JAMA Network Standard initiation procedures (SP) for extended-release (XR)-naltrexone can be a barrier to initiation for patients. In this stepped-wedge cluster-randomized trial, they compared SP initiation (3-5 days buprenorphine taper, 7-10 days opioid-free) to a rapid procedure (RP) initiation (1 day buprenorphine, 1 day opioid free, 3-4 days ascending dose of oral naltrexone). Patients in the RP group (62.7%) were more likely to receive the initial XR-naltrexone dose (OR 3.6, P

At the California Academy of Family Physicians, we know that Addiction Medicine is Family Medicine. In our latest series 1 in 5, we bring you stories of doctors - and their patients - who have worked together to reduce the harm done by opioid use disorder (OUD). These brief stories will bring you into the hearts and minds of our guests. We hope that this will inspire you to do everything in your power to bring medical attention to the OUD patients in your practice.  Episode 4: I Leaned In: One Family Doc's Story of Treating Opioid Use Disorder In this episode we meet with a leader in family medicine. A practicing family doc and health system administrator who shares his journey toward treating OUD. Guests: Dr. Jay W. Lee, MD, MPH, FAAFP is a board-certified family physician who sees patients at KCS Health, a community health center serving patients who have immigrated or who have been impacted by the carceral system in Orange County, CA. He also serves as medical director at Integrated Health Partners, a clinically-integrated network serving 350,000 patients insured mostly by Medicaid whose medical home is at one of 9 community health centers in 3 counties. Dr. Lee co-founded the Family Medicine Revolution hashtag: #FMRevolution, a grassroots social media movement giving the power of telling family medicine's story back to family physicians and building a global community of thought leaders. Our interviewer, Dr. Tipu Khan, MD, FAAFP, FASAM is the Medical Director of the Ventura County Backpack Medicine Group, Primary Care Hepatitis C Eradication Project. He is also Chief of the Ventura County Addiction Medicine Specialty clinic and consultation service, with a speciality in SUD in pregnancy.   The Family Docs Podcast is hosted by Rob Assibey, MD, FAAFP. Resources CAFP's SUD webpage, including MOUD Champions https://familydocs.org Article: Stigma Against Patients With Substance Use Disorders Among Health Care Professionals and Trainees and Stigma-Reducing Interventions: A Systematic Review The Bridge (formerly CA Bridge) https://bridgetotreatment.org  UCSF Warm Line https://nccc.ucsf.edu/clinician-consultation/substance-use-management Series Information The Family Docs Podcast series 1 in 5 is supported by the California Department of Health Care Services (DHCS).  The Family Docs podcast is developed, produced, and recorded by the California Academy of Family Physicians. The views and opinions expressed in this program are those of the speakers and do not necessarily reflect the views or positions of any entities they represent or the California Academy of Family Physicians. Copyright 2024, California Academy of Family Physicians. More information at www.familydocs.org/podcast. Visit the California Academy of Family Physicians online at www.familydocs.org. Follow us on social media: Twitter - https://twitter.com/cafp_familydocs Instagram - https://www.instagram.com/cafp_familydocs Facebook - https://www.facebook.com/familydocs    

 Washington, DC, May 17, 2024 — On this month's podcast, the National Association of County and City Health Officials' (NACCHO) Adriane Casalotti, Chief of Government and Public Affairs, and Victoria Van de Vate, Director of Government Affairs discussed the current status of the H5N1 avian “bird” flu outbreak in dairy cattle and the situation on coordinating a federal-level response, from making personal protective equipment (PPE) readily available to testing livestock and farmworkers. The Centers for Disease Control and Prevention (CDC) recommends that local health departments connect individuals to testing if they observe an increase in sick animals and farmworkers, utilize CDC communication resources, and ensure that farms and farmworkers have access to PPE.   Later in the program (13:24), Elana Filipos, Program Analyst on the Maternal, Child, and Adolescent Health team at NACCHO, and Mary “Maret” Wachira, Health Educator Consultant and IBCLC at the Florida Department of Health in Citrus County (DOH-Citrus), discussed how DOH-Citrus initiated a pilot program to provide prenatal care and treatment for pregnant people with substance use disorders (SUDs). Drug overdose deaths in pregnant and postpartum women increased significantly between early 2018 to late 2021, according to a recent study by researchers at the National Institute on Drug Abuse at the National Institutes of Health. However, pregnant people seeking support for an SUD during the perinatal period may face stigmatizing barriers to care that prevent them from accessing medical treatment and behavioral interventions. To address this growing public health concern, DOH-Citrus implemented a holistic prenatal care service model that incorporates Medication for Opioid Use Disorder services and mental health counseling during routine prenatal care appointments to improve outcomes for pregnant people and infants in their community.   Learn more about the Citrus County program via a journal article published in the Maternal and Child Health Journal, titled “Addressing Perinatal Opioid Use at a Local Health Department in Florida.”    ###   About NACCHO The National Association of County and City Health Officials (NACCHO) represents the over 3,300 local governmental health departments across the country. These city, county, metropolitan, district, and tribal departments work every day to protect and promote health and well-being for all people in their communities. For more information, visit www.naccho.org.

Can antibodies be used as biomarkers of naturally resolving peanut allergy? Find out about this and more in today's PeerDirect Medical News Podcast.

31-40 Round-Up  Quick summaries of Episodes 31-40.    31. Injection Drug Use Frequency Before and After Take-Home Naloxone Training    32. Trazodone for sleep disturbance in opioid dependent patients maintained on buprenorphine: A double blind, placebo-controlled trial.    33. Non-fatal overdose risk associated with prescribing opioid agonists concurrently with other medication: Cohort study conducted using linked primary care, secondary care and mortality records    34. Buprenorphine Dose and Time to Discontinuation Among Patients With Opioid Use Disorder in the Era of Fentanyl    35. Removal of Medicaid Prior Authorization Requirements and Buprenorphine Treatment for Opioid Use Disorder    36. Emotion dysregulation factors associated with problematic smartphone use severity: The mediating role of fear of missing out    37. Superiority and cost-effectiveness of monthly extended-release buprenorphine versus daily standard of care medication: a pragmatic, parallel-group, open-label, multicentre, randomised, controlled, phase 3 trial    38. Receipt of Opioid Use Disorder Treatments Prior to Fatal Overdoses and Comparison to No Treatment in Connecticut, 2016-17    39. Effects of Abstinence From Opioid on Neuropsychological Performance in Men With Opioid Use Disorder: A Longitudinal Study    40. Drug overdose risk with benzodiazepine treatment in young adults: Comparative analysis in privately and publicly insured individuals  ----------  31-40 Round-Up Credits:  Original theme music: composed and performed by Benjamin Kennedy  Audio production: Erin McCue  Executive Producer: Dr. Patrick Beeman  A podcast from Ars Longa Media  ----------  This is Addiction Medicine Journal Club with Dr. Sonya Del Tredici and Dr. John Keenan. We practice addiction medicine and primary care, and we believe that addiction is a disease that can be treated. This podcast reviews current articles to help you stay up to date with research that you can use in your addiction medicine practice.     The best part of any journal club is the conversation. Send us your comments on social media or join our Facebook group.    Email: addictionmedicinejournalclub@gmail.com   Facebook: @AddictionMedJC  Facebook Group: Addiction Medicine Journal Club  Instagram: @AddictionMedJC   Threads: @AddictionMedJC  Twitter/X: @AddictionMedJC    YouTube: addictionmedicinejournalclub    Addiction Medicine Journal Club is intended for educational purposes only and should not be considered medical advice. The views expressed here are our own and do not necessarily reflect those of our employers or the authors of the articles we review. All patient information has been modified to protect their identities. 

At the California Academy of Family Physicians, we know that Addiction Medicine is Family Medicine. In our latest series 1 in 5, we bring you stories of doctors - and their patients - who have worked together to reduce the harm done by opioid use disorder (OUD). These brief stories will bring you into the hearts and minds of our guests. We hope that this will inspire you to do everything in your power to bring medical attention to the OUD patients in your practice.  Episode 2: The Beauty of the Bus: Meeting Opioid Use Disorder on the Road This episode brings us up close with the life-long work of a compassionate, no-nonsense doctor... The ultimate patient advocate who has touched thousands of lives through his unique, home-grown outreach program.  Guests: Dr. Marc D. Lasher, DO specializes in addiction medicine, diagnosing and treating patients with substance abuse issues with the goal of achieving recovery. He attended his family medicine residency at UCSF Fresno and remains in Fresno today. He has offices in Aegis Medical System, and Adventist Health, and runs a free clinic on Saturdays out of a refurbished bus. In his words, “I treat addiction as a chronic disease.” “There are human beings behind addiction and a strong need for someone to touch people's lives without stigma and taboos.” Our interviewer, Dr. Tipu Khan, MD, FAAFP, FASAM is the Medical Director of the Ventura County Backpack Medicine Group, Primary Care Hepatitis C Eradication Project. He is also Chief of the Ventura County Addiction Medicine Specialty clinic and consultation service, with a speciality in SUD in pregnancy.  The Family Docs Podcast is hosted by Rob Assibey, MD, FAAFP.   Resources Epistle of Larry the Counselor  CAFP's SUD webpage, including MOUD Champions https://familydocs.org Article: Stigma Against Patients With Substance Use Disorders Among Health Care Professionals and Trainees and Stigma-Reducing Interventions: A Systematic Review The Bridge (formerly CA Bridge) https://bridgetotreatment.org  UCSF Warm Line https://nccc.ucsf.edu/clinician-consultation/substance-use-management/  More about Dr. Lasher and the Bus: More information on Dr. Lasher's website: https://freeclinic-exchange.org A film on Dr. Lasher's work, The Clinic Central Valley Physicians Magazine, Spring 2020 To see images of Dr. Lasher, the bus, and Dr. Larry Park, visit familydocs.org/podcast.   Series Information The Family Docs Podcast series 1 in 5 is supported by the California Department of Health Care Services (DHCS).  The Family Docs podcast is developed, produced, and recorded by the California Academy of Family Physicians. The views and opinions expressed in this program are those of the speakers and do not necessarily reflect the views or positions of any entities they represent or the California Academy of Family Physicians. Copyright 2024, California Academy of Family Physicians. More information at www.familydocs.org/podcast. Visit the California Academy of Family Physicians online at www.familydocs.org. Follow us on social media: Twitter - https://twitter.com/cafp_familydocs Instagram - https://www.instagram.com/cafp_familydocs Facebook - https://www.facebook.com/familydocs

In this episode we tackle opioid use disorder during pregnancy with OB-GYN Dr. Kenneth Spielvogel. Dr. Grover and Dr. Spielvogel discuss multiple topics including the use of methadone and buprenorphine during pregnancy, overdoses during pregnancy, fentanyl exposure during pregnancy, and breastfeeding while taking buprenorphine.

What are the hypothesized neurobiological mechanisms that support the use of cannabidiol (CBD) as a treatment for opioid use disorder (OUD)? How does CBD influence cue-induced craving in OUD? What are the challenges and opportunities in further exploring the use of CBD as a potential treatment for OUD? Dr. Joji Suzuki is the Director of the Division of Addiction Psychiatry and Director of Addictions Education in the Department of Psychiatry, Brigham and Women's Hospital, and an Assistant Professor of Psychiatry at Harvard Medical School. His areas of clinical and research interests are the assessment and management of substance use disorders and related conditions in general medical settings, motivational interviewing, office-based opioid treatment, implementation of collaborative models of care, and medical education. He is the site director for the Partners Addiction Psychiatry Fellowship, and is involved with teaching medical students, residents, and allied health professionals. He has authored over 30 peer-reviewed manuscripts and book chapters related to addiction psychiatry.

Join physician Jill Becker as we delve into the world of medication-assisted therapy (MAT) for opioid use disorder. Discover why MAT is crucial, the challenges patients face, and how Jill's compassionate approach sets her apart from the norm in the medical field. Jill Becker is a physician. She discusses the KevinMD article, "A doctor's genuine approach to medication-assisted therapy patients." Our presenting sponsor is Nuance, a Microsoft company. Do you spend more time on administrative tasks like clinical documentation than you do with patients? You're not alone. Clinicians report spending up to two hours on administrative tasks for each hour of care provided. Nuance, a Microsoft company, is committed to helping clinicians restore the balance with Dragon Ambient eXperience – or DAX for short. DAX is an AI-powered, voice-enabled solution that helps physicians cut documentation time in half. DAX Copilot combines proven conversational and ambient AI with the most advanced generative AI in a mobile application that integrates directly with your existing workflows. DAX Copilot can be easily enabled within the workflow of the Dragon Medical application to bring the power of ambient technology to more clinicians faster while leveraging the proven and powerful capabilities used by over 550,000 physicians. Explore DAX Copilot today. Visit https://nuance.com/daxinaction to see a 12-minute DAX Copilot demo. Discover clinical documentation that writes itself and reclaim your work-life balance. VISIT SPONSOR → https://nuance.com/daxinaction SUBSCRIBE TO THE PODCAST → https://www.kevinmd.com/podcast RECOMMENDED BY KEVINMD → https://www.kevinmd.com/recommended GET CME FOR THIS EPISODE → https://earnc.me/TYuVAr Powered by CMEfy.